Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples

Table 1 Performance characteristics of Genotype MTBDRplus VER 2.0 LPA for detection RMP and INH resistance and MDR-TB in smear positive direct sample, 2015

Detection of drug resistance	MGIT R	MGIT S	LPA R	LPA S	Sensitivity%	Specificity%	PPV%	NPV%
Detection of drug resistance	MGIT R	MGIT S	LPA R	LPA S	(95%* CI)	(95%* CI)	(95%* CI)	(95%* CI)
*RMP	34	38	34	38	88.2 (72.6–96.7)	89.5 (75.2–97.1)	88.2 (72.6–96.7)	89.5 (75.2–97.1)
*INH	36	36	34	38	91.7 (77.5–98.3)	97.2 (85.5–99.9)	97.1 (84.7–99.9)	92.1 (78.6–98.3)
*MDR-TB (RMP&INH)	28	31	27	32	96.4 (81.7–99.9)	100 (88.8–100)	100 (87.2–100)	96.9 (83.8–99.9)

*RMP Rifampicin, INH Isoniazid, MDR-TB Multidrug resistant Tuberculosis, R Resistant, S Susceptible, CI Confidence Interval

ISSN: 1471-2334